Ocean Biomedical, Inc. (OCEA)

Market Cap	116.18K -99.2%
Revenue (ttm)	n/a
Net Income	-30.72M
EPS	-0.71
Shares Out	232.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101
Average Volume	62,979
Open	0.0005
Previous Close	0.0006
Day's Range	0.0002 - 0.0005
52-Week Range	n/a
Beta	1.62
RSI	46.19
Earnings Date	Apr 2, 2026

About Ocean Biomedical

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company’s oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: OCEA